SEARCH

SEARCH BY CITATION

References

  • 1
    Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:310.
  • 2
    Zatloukal P, Kanitz E, Magyar P, et al. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: The Central European Phase II study. Lung Cancer 1998;22:243250.
  • 3
    Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Williston Park) 2001;15:1114.
  • 4
    Lund B, Hansen OP, Neijt JP, et al. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs 1995;6 (Suppl 6):6162.
  • 5
    Nabhan C, Krett N, Gandhi V, et al. Gemcitabine in hematologic malignancies. Curr Opin Oncol 2001;13:514521.
  • 6
    Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997;24:S7-2S7-7.
  • 7
    Heinemann V, Schulz L, Issels RD, et al. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 1995;22:1118.
  • 8
    Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997;24:S7-24S27-28.
  • 9
    Kosarek CE, Kisseberth WC, Gallant SL, et al. Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies. J Vet Intern Med 2005;19:8186.
  • 10
    Turner AI, Hahn KA, Rusk A, et al. Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma. J Vet Intern Med 2006;20:13841388.
  • 11
    LeBlanc AK, LaDue TA, Turrel JM, et al. Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: A veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 2004;45:466470.
  • 12
    Jones PD, De Lorimier LP, Kitchell BE, et al. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc 2003;39:463467.
  • 13
    Freise KJ, Martin-Jimenez T. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. J Vet Pharmacol Ther 2006;29:137145.
  • 14
    Freise KJ, Martin-Jimenez T. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. J Vet Pharmacol Ther 2006;29:147152.
  • 15
    Reed E. Cisplatin, carboplatin, and oxaliplatin. In: ChabnerBA, LongoDL, eds. Cancer Chemotherapy and Biotherapy, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:332343.
  • 16
    Johnson SW, O'Dwyer PJ. Cisplatin and its analogues. In: DeVitaVT, HellmanS, RosenbergSA, eds. Cancer: Principles and Practice of Oncology, 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:344358.
  • 17
    Kisseberth WC, Vail DM, Yaissle J, et al. Phase I clinical evaluation of carboplatin in tumor-bearing cats: A Veterinary Cooperative Oncology Group study. J Vet Intern Med 2008;22:8388.
  • 18
    Hahn KA, McEntee MF, Daniel GB, et al. Hematologic and systemic toxicoses associated with carboplatin administration in cats. Am J Vet Res 1997;58:677679.
  • 19
    Theon AP, VanVechten MK, Madewell BR. Intratumoral administration of carboplatin for treatment of squamous cell carcinomas of the nasal plane in cats. Am J Vet Res 1996;57:205210.
  • 20
    Dhaliwal RS, Johnson TO, Kitchell BE. Primary extraskeletal hepatic osteosarcoma in a cat. J Am Vet Med Assoc 2003;222:340342, 316.
  • 21
    Spugnini EP, Ruslander D, Bartolazzi A. Extraskeletal osteosarcoma in a cat. J Am Vet Med Assoc 2001;219:6062, 49.
  • 22
    Van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999;80:981990.
  • 23
    Crul M, Van Waardenburg RC, Bocxe S, et al. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 2003;65:275282.
  • 24
    Peters GJ, Bergman AM, Ruiz van Haperen VW, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;22:7279.
  • 25
    Bergman AM, Ruiz van Haperen VW, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521530.
  • 26
    Villella J, Marchetti D, Odunsi K, et al. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. Gynecol Oncol 2004;95:539545.
  • 27
    Rose PG, Mossbruger K, Fusco N, et al. Gemcitabine reverses cisplatin resistance: Demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003;88:1721.
  • 28
    Bang S, Jeon TJ, Kim MH, et al. Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma. Pancreatology 2006;6:635641.
  • 29
    Abratt RP, Hacking DJ, Goedhals L, et al. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma. Semin Oncol 1997;24:S8-18S18-23.
  • 30
    Voigt W, Bulankin A, Muller T, et al. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 2000;6:20872093.
  • 31
    Xiros N, Papacostas P, Economopoulos T, et al. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: A phase II multicenter study by the Hellenic Cooperative Oncology Group. Ann Oncol 2005;16:773779.
  • 32
    Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000;36:395403.
  • 33
    Mauldin GN, Matus RE, Patnaik AK, et al. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med 1988;2:6065.
  • 34
    Ogilvie GK, Moore AS, Obradovich JE, et al. Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. J Am Vet Med Assoc 1993;202:18391844.
  • 35
    Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol 1988;4:121141.
  • 36
    Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:39463952.